In response to the COVID-19 pandemic, my institution has implemented multiple procedures to protect patients and personnel from COVID-19 infection and avoid interruptions in cancer therapy.
Immunotherapies have revolutionized the treatment of metastatic recurrent head and neck cancer. In this commentary, I revisit the data behind current best practice and look ahead to new combination therapies.
Read my commentary to see my approach to patients with head and neck cancer and an NTRK gene fusion.
Read my commentary to see my approach to managing immunotherapy-related adverse events in patients with head and neck cancer.